Search

The toxicity profile of fac -[Re(CO) 3 (N-N)L] + complexes against microbial and tumoral cells has been extensively studied, primarily focusing on modifications to the bidentate diimine (N-N) ligand. However, less attention has been paid to modifications of the axial ligand L, which is perpendicular to the Re-N-N plane. This study reveals that the high toxicity of the fac -[Re(CO) 3 (bpy)(Ctz)] + complex may be attributed to the structural effect of the trityl (CPh 3 ) group present in clotrimazole, as removal of phenyl rings causes a significant decrease in the activity against Staphylococcus aureus ( S. aureus ). Moreover, substitution of the 1-tritylimidazole ligand by the structurally related ligands PPh 3 and PCy 3 maintains similarly high activity levels. These findings contribute to understanding the interactions of toxic complexes with bacterial membranes, suggesting that the ligand structures play a crucial role in inhibiting cell wall synthesis processes, potentially including Lipid II synthesis. Compounds with Ph 3 E (E = C-imidazole; P) groups also showed to be 10 times more toxic than cisplatin against three mammalian cell lines (IC 50 : 2-4 μM). In contrast, the analogue 1-benzylimidazole and 1- tert -butylimidazole derivatives were as toxic as cisplatin. We observed that the decomposition of the [Re (I) (CO) 3 ] fragment inside mammalian cell lines liberates CO, which is expected to exert biological effects. Therefore, compounds of this family possessing the structural motif Ph 3 E seem to combine high antimicrobial and antitumoral activities, the latter being much higher than that of cisplatin.

Arsenic contamination of groundwater is among one of the biggest health threats affecting millions of people in the world. There is an urgent need for efficient arsenic biosensors where the use of arsenic metabolizing enzymes can be explored. In this work, we have solved four crystal structures of arsenite oxidase (Aio) in complex with arsenic and antimony oxyanions and the structures determined correspond to intermediate states of the enzymatic mechanism. These structural data were complemented with density-functional theory calculations providing a unique view of the molybdenum active site at different time points that, together with mutagenesis data, enabled to clarify the enzymatic mechanism and the molecular determinants for the oxidation of As(III) to the less toxic As(V) species., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)

Carbon monoxide (CO) is a cytoprotective endogenous gas that is ubiquitously produced by the stress response enzyme heme-oxygenase. Being a gas, CO rapidly diffuses through tissues and binds to hemoglobin (Hb) increasing carboxyhemoglobin (COHb) levels. COHb can be formed in erythrocytes or in plasma from cell-free Hb. Herein, it is discussed as to whether endogenous COHb is an innocuous and inevitable metabolic waste product or not, and it is hypothesized that COHb has a biological role. In the present review, literature data are presented to support this hypothesis based on two main premises: (i) there is no direct correlation between COHb levels and CO toxicity, and (ii) COHb seems to have a direct cytoprotective and antioxidant role in erythrocytes and in hemorrhagic models in vivo. Moreover, CO is also an antioxidant by generating COHb, which protects against the pro-oxidant damaging effects of cell-free Hb. Up to now, COHb has been considered as a sink for both exogenous and endogenous CO generated during CO intoxication or heme metabolism, respectively. Hallmarking COHb as an important molecule with a biological (and eventually beneficial) role is a turning point in CO biology research, namely in CO intoxication and CO cytoprotection.

Several metal-based carbon monoxide-releasing molecules (CORMs) are active CO donors with established antibacterial activity. Among them, CORM conjugates with azole antibiotics of type [Mn(CO) 3 (2,2'-bipyridyl)(azole)] + display important synergies against several microbes. We carried out a structure-activity relationship study based upon the lead structure of [Mn(CO) 3 (Bpy)(Ctz)] + by producing clotrimazole (Ctz) conjugates with varying metal and ligands. We concluded that the nature of the bidentate ligand strongly influences the bactericidal activity, with the substitution of bipyridyl by small bicyclic ligands leading to highly active clotrimazole conjugates. On the contrary, the metal did not influence the activity. We found that conjugate [Re(CO) 3 (Bpy)(Ctz)] + is more than the sum of its parts: while precursor [Re(CO) 3 (Bpy)Br] has no antibacterial activity and clotrimazole shows only moderate minimal inhibitory concentrations, the potency of [Re(CO) 3 (Bpy)(Ctz)] + is one order of magnitude higher than that of clotrimazole, and the spectrum of bacterial target species includes Gram-positive and Gram-negative bacteria. The addition of [Re(CO) 3 (Bpy)(Ctz)] + to Staphylococcus aureus causes a general impact on the membrane topology, has inhibitory effects on peptidoglycan biosynthesis, and affects energy functions. The mechanism of action of this kind of CORM conjugates involves a sequence of events initiated by membrane insertion, followed by membrane disorganization, inhibition of peptidoglycan synthesis, CO release, and break down of the membrane potential. These results suggest that conjugation of CORMs to known antibiotics may produce useful structures with synergistic effects that increase the conjugate's activity relative to that of the antibiotic alone., Competing Interests: The authors declare no competing financial interest., (© 2022 The Authors. Published by American Chemical Society.)

Microglia are the immune competent cell of the central nervous system (CNS), promoting brain homeostasis and regulating inflammatory response against infection and injury. Chronic or exacerbated neuroinflammation is a cause of damage in several brain pathologies. Endogenous carbon monoxide (CO), produced from the degradation of heme, is described as anti-apoptotic and anti-inflammatory in several contexts, including in the CNS. Neuroglobin (Ngb) is a haemoglobin-homologous protein, which upregulation triggers antioxidant defence and prevents neuronal apoptosis. Thus, we hypothesised a crosstalk between CO and Ngb, in particular, that the anti-neuroinflammatory role of CO in microglia depends on Ngb. A novel CO-releasing molecule (ALF826) based on molybdenum was used for delivering CO in microglial culture.BV-2 mouse microglial cell line was challenged with lipopolysaccharide (LPS) for triggering inflammation, and after 6 h ALF826 was added. CO exposure limited inflammation by decreasing inducible nitric oxide synthase (iNOS) expression and the production of nitric oxide (NO) and tumour necrosis factor-α (TNF-α), and by increasing interleukine-10 (IL-10) release. CO-induced Ngb upregulation correlated in time with CO's anti-inflammatory effect. Moreover, knocking down Ngb reversed the anti-inflammatory effect of CO, suggesting that dependents on Ngb expression. CO-induced Ngb upregulation was independent on ROS signalling, but partially dependent on the transcriptional factor SP1. Finally, microglial cell metabolism is also involved in the inflammatory response. In fact, LPS treatment decreased oxygen consumption in microglia, indicating a switch to glycolysis, which is associated with a proinflammatory. While CO treatment increased oxygen consumption, reverting LPS effect and indicating a metabolic shift into a more oxidative metabolism. Moreover, in the absence of Ngb, this phenotype was no longer observed, indicating Ngb is needed for CO's modulation of microglial metabolism. Finally, the metabolic shift induced by CO did not depend on alteration of mitochondrial population. In conclusion, neuroglobin emerges for the first time as a key player for CO signalling against exacerbated inflammation in microglia., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Microglia, the 'resident immunocompetent cells' of the central nervous system (CNS), are key players in innate immunity, synaptic refinement and homeostasis. Dysfunctional microglia contribute heavily to creating a toxic inflammatory milieu, a driving factor in the pathophysiology of several CNS disorders. Therefore, strategies to modulate the microglial function are required to tackle exacerbated tissue inflammation. Carbon monoxide (CO), an endogenous gaseous molecule produced by the degradation of haem, has anti-inflammatory, anti-apoptotic, and pro-homeostatic and cytoprotective roles, among others. ALF-826A, a novel molybdenum-based CO-releasing molecule, was used for the assessment of neuron-microglia remote communication. Primary cultures of rat microglia and neurons, or the BV-2 microglial and CAD neuronal murine cell lines, were used to study the microglia-neuron interaction. An approach based on microglial-derived conditioned media in neuronal culture was applied. Medium derived from CO-treated microglia provided indirect neuroprotection against inflammation by limiting the lipopolysaccharide (LPS)-induced expression of reactivity markers (CD11b), the production of reactive oxygen species (ROS) and the secretion of inflammatory factors (TNF-α, nitrites). This consequently prevented neuronal cell death and maintained neuronal morphology. In contrast, in the absence of inflammatory stimulus, conditioned media from CO-treated microglia improved neuronal morphological complexity, which is an indirect manner of assessing neuronal function. Likewise, the microglial medium also prevented neuronal cell death induced by pro-oxidant tert-Butyl hydroperoxide (t-BHP). ALF-826 treatment reinforced microglia secretion of Interleukin-10 (IL-10) and adenosine, mediators that may protect against t-BHP stress in this remote communication model. Chemical inhibition of the adenosine receptors A 2A and A 1 reverted the CO-derived neuroprotective effect, further highlighting a role for CO in regulating neuron-microglia communication via purinergic signalling. Our findings indicate that CO has a modulatory role on microglia-to-neuron communication, promoting neuroprotection in a non-cell autonomous manner. CO enhances the microglial release of neurotrophic factors and blocks exacerbated microglial inflammation. CO improvement of microglial neurotrophism under non-inflammatory conditions is here described for the first time., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

CO-releasing molecules (CORMs) have been widely studied for their anti-inflammatory, antiapoptotic, and antiproliferative effects. CORM-3 is a water-soluble Ru-based metal carbonyl complex, which metallates serum proteins and readily releases CO in biological media. In this work, we evaluated the anti-inflammatory and wound-healing effects of gold nanoparticles-CORM-3 conjugates, AuNPs@PEG@BSA·Ru(CO) x , exploring its use as an efficient CO carrier. Our results suggest that the nanoformulation was capable of inducing a more pronounced cell effect, at the anti-inflammatory level and a faster tissue repair, probably derived from a rapid cell uptake of the nanoformulation that results in the increase of CO inside the cell.

In the last decade, carbon monoxide-releasing molecules (CORMs) have been shown to act against several pathogens and to be promising antimicrobials. However, the understanding of the mode of action and reactivity of these compounds on bacterial cells is still deficient. In this work, we used a metabolomics approach to probe the toxicity of the ruthenium(II) complex Ru(CO) 3 Cl(glycinate) (CORM-3) on Escherichia coli By resorting to 1 H nuclear magnetic resonance, mass spectrometry, and enzymatic activities, we show that CORM-3-treated E. coli accumulates larger amounts of glycolytic intermediates, independently of the oxygen growth conditions. The work provides several evidences that CORM-3 inhibits glutamate synthesis and the iron-sulfur enzymes of the tricarboxylic acid (TCA) cycle and that the glycolysis pathway is triggered in order to establish an energy and redox homeostasis balance. Accordingly, supplementation of the growth medium with fumarate, α-ketoglutarate, glutamate, and amino acids cancels the toxicity of CORM-3. Importantly, inhibition of the iron-sulfur enzymes glutamate synthase, aconitase, and fumarase is only observed for compounds that liberate carbon monoxide. Altogether, this work reveals that the antimicrobial action of CORM-3 results from intracellular glutamate deficiency and inhibition of nitrogen and TCA cycles., (Copyright © 2019 American Society for Microbiology.)

Therapy with inhaled carbon monoxide (CO) is being tested in human clinical trials, yet the alternative use of prodrugs, CO-Releasing Molecules (CORMs), is conceptually advantageous. These molecules are designed to release carbon monoxide in specific tissues, in response to some locally expressed stimulus, where CO can trigger a cytoprotective response. The design of such prodrugs, mostly metal carbonyl complexes, must consider their ADMET profiles, including their interaction with transport plasma proteins. However, the molecular details of this interaction remain elusive. To shed light into this matter, we focused on the CORM prototype [Mo(η5-Cp)(CH2COOH)(CO)3] (ALF414) and performed a detailed molecular characterization of its interaction with bovine serum albumin (BSA), using spectroscopic and computational methods. The experimental results show that ALF414 partially quenches the intrinsic fluorescence of BSA without changing its secondary structure. The interaction between BSA and ALF414 follows a dynamic quenching mechanism, indicating that no stable complex is formed between the protein Trp residues and ALF414. The molecular dynamics simulations are in good agreement with the experimental results and confirm the dynamic and unspecific character of the interaction between ALF414 and BSA. The simulations also provide important insights into the nature of the interactions of this CORM prototype with BSA, which are dominated by hydrophobic contacts, with a contribution from hydrogen bonding. This kind of information is useful for future CORM design., Competing Interests: CCR was co-founder and manager of Alfama Lda and Board member of Alfama Inc until 2017. CCR is a stockholder of Proterris Inc. Proterris Inc does not have any restrictions on sharing the present data and adheres to the PLOS ONE policies on sharing data and materials.

Aluminum-based metal-organic frameworks (MOFs), [Al(OH)(SDC)] n , (H 2 SDC: 4,4'-stilbenedicarboxylic acid), also known as CYCU-3, were prepared by means of the coordination modulation method to produce materials with different crystal size and morphology. In particular, we screened several reagent concentrations (20-60 mM) and modulator/ligand ratios (0-50), leading to 20 CYCU x_ y materials ( x: reagent concentration, y = modulator/ligand ratio) with different particle size and morphology. Noteworthy, the use of high modulator/ligand ratio gives rise to a new phase of CYCU-3 (CYCU-3' x_50 series), which was structurally analyzed. Afterward, to test the potential of these materials as CO-prodrug carriers, we selected three of them to adsorb the photo- and bioactive CO-releasing molecule (CORM) ALF794 [Mo(CNCMe 2 CO 2 H) 3 (CO) 3 ] (CNCMe 2 CO 2 H = 2-isocyano-2-methyl propionic acid): (i) CYCU-3 20_0, particles in the nanometric range; (ii) CYCU-3 50_5, bar-type particles with heterogeneous size, and (iii) CYCU-3' 50_50, a new phase analogous to pristine CYCU-3. The corresponding hybrid materials were fully characterized, revealing that CYCU-3 20_0 with the smallest particle size was not stable under the drug loading conditions. Regarding the other two materials, similar ALF794 loadings were found (0.20 and 0.19 CORM/MOF molar ratios for ALF794@CYCU-3 50_5 and ALF794@CYCU-3' 50_50, respectively). In addition, these hybrid systems behave as CO-releasing materials (CORMAs), retaining the photoactive properties of the pristine CORM in both phosphate saline solution and solid state. Finally, the metal leaching studies in solution confirmed that ALF794@CYCU-3' 50_50 shows a good retention capacity toward the potentially toxic molybdenum fragments (75% of retention after 72 h), which is the lowest value reported for a MOF-based CORMA to date.

Mesoporous silica Al-MCM-41 nanoparticles have been used, for the first time, as vehicles for the single and dual encapsulation of the cationic CO-releasing molecule (CORM) [Mn(1,4,7-triazacyclononane)(CO) 3 ] + (ALF472 + ) and the well-known antineoplastic drug, cis-[PtCl 2 (NH 3 ) 2 ] (cisplatin). Thus, two new hybrid materials, namely, ALF472@Al-MCM-41 and ALF472-cisplatin@Al-MCM-41, have been isolated and fully characterized. The results reveal that the presence of CORM molecules enhances cisplatin loading 3-fold, yielding a cargo of 0.45 mmol g -1 of ALF472 + and 0.12 mmol g -1 of the platinum complex for ALF472-cisplatin@Al-MCM-41. It is worth noting that ALF472@Al-MCM-41 shows a good dispersion in phosphate buffered saline solution, while the dual hybrid material slightly aggregates in this simulated physiological medium (hydrodynamic size: 112 ± 23 and 336 ± 50 nm, respectively). In addition, both hybrid materials (ALF472@Al-MCM-41 and ALF472-cisplatin@Al-MCM-41) behave as photoactive CO-releasing materials, delivering 0.25 and 0.11 equiv of CO, respectively, after 24 h and exhibiting a more controlled CO delivery than that of the free CORM. Finally, metal leaching studies have confirmed the good retention capacity of Al-MCM-41 toward the potentially toxic manganese fragments (86% of retention after 72 h) as well as the low release of cisplatin (ca. 7% after 72 h).

A novel CO releasing material has been prepared via a one-pot synthesis-encapsulation strategy using the hierarchical metal organic framework [Zn 2 (dhtp)] (dhtp = 2,5-dihydroxyterephthalate) as a host of the photoactivable molybdenum tricarbonyl complex [Mo(CNCMe 2 CO 2 H) 3 (CO) 3 ].

The encapsulation of the photoactive, nontoxic, water-soluble, and air-stable cationic CORM [Mn(tacn)(CO)3]Br (tacn = 1,4,7-triazacyclononane) in different inorganic porous matrixes, namely, the metalorganic framework bio-MOF-1, (NH2(CH3)2)2[Zn8(adeninate)4(BPDC)6]·8DMF·11H2O (BPDC = 4,4'-biphenyldicarboxylate), and the functionalized mesoporous silicas MCM-41-SO3H and SBA-15-SO3H, is achieved by a cation exchange strategy. The CO release from these loaded materials, under simulated physiological conditions, is triggered by visible light. The results show that the silica matrixes, which are unaltered under physiological conditions, slow the kinetics of CO release, allowing a more controlled CO supply. In contrast, bio-MOF-1 instability leads to the complete leaching of the CORM. Nevertheless, the degradation of the MOF matrix gives rise to an enhanced CO release rate, which is related to the presence of free adenine in the solution.

Transition metal carbonyl complexes used as CO-releasing molecules (CORMs) for biological and therapeutic applications may exhibit interesting antimicrobial activity. However, understanding the chemical traits and mechanisms of action that rule this activity is required to establish a rationale for the development of CORMs into useful antibiotics. In this work the bactericidal activity, the toxicity to eukaryotic cells, and the ability of CORMs to deliver CO to bacterial and eukaryotic cells were analysed for a set of seven CORMs that differ in the transition metal, ancillary ligands and the CO release profile. Most of these CORMs exhibited bactericidal properties that decrease in the following order: CORM-2 > CORM-3 > ALF062 > ALF850 > ALF186 > ALF153 > [Fe(SBPy3)(CO)](BF4)2. A similar yet not entirely coincident decreasing order was found for their induction of intracellular reactive oxygen species (ROS) in E. coli. In contrast, studies in model animal cells showed that for any given CORM, the level of intracellular ROS generated was negligible when compared with that measured inside bacteria. Importantly, these CORMs were in general not toxic to eukaryotic cells, namely murine macrophages, kidney LLC-PK1 epithelial cells, and liver cell line HepG2. CORM-2 and CORM-3 delivered CO to the intracellular space of both E. coli and the two types of tested eukaryotic cells, yet toxicity was only elicited in the case of E. coli. CO delivered by ALF186 into the intercellular space did not enter E. coli cells and the compound was not toxic to either bacteria or to eukaryotic cells. The Fe(ii) carbonyl complex [Fe(SBPy3)(CO)](2+) had the reverse, undesirable toxicity profile, being unexpectedly toxic to eukaryotic cells and non-toxic to E. coli. ALF153, the most stable complex in the whole set, was essentially devoid of toxicity or ROS induction ability in all cells. These results suggest that CORMs have a relevant therapeutic potential as antimicrobial drugs since (i) they can show opposite toxicity profiles towards bacteria and eukaryotic cells; (ii) their activity can be modulated through manipulation of the ancillary ligands, as shown with the three {Ru(CO)3}(2+) and two zerovalent Mo based CORMs; and (iii) their toxicity to eukaryotic cells can be made acceptably low. With this new approach, this work contributes to the understanding of the roots of the bactericidal action of CORMs and helps in establishing strategies for their development into a new class of antibiotics.

We have designed and synthesised a [Ru(CO)3 Cl2 (NAC)] pro-drug that features an N-acetyl cysteine (NAC) ligand. This NAC carbon monoxide releasing molecule (CORM) conjugate is able to simultaneously release biologically active CO and to ablate the concurrent formation of reactive oxygen species (ROS). Complexes of the general formulae [Ru(CO)3 (L)3 ](2+) , including [Ru(CO)3 Cl(glycinate)] (CORM-3), have been shown to produce ROS through a water-gas shift reaction, which contributes significantly, for example, to their antibacterial activity. In contrast, NAC-CORM conjugates do not produce ROS or possess antibacterial activity. In addition, we demonstrate the synergistic effect of CO and NAC both for the inhibition of nitric oxide (formation) and in the expression of tumour-necrosis factor (TNF)-α. This work highlights the advantages of combining a CO-releasing scaffold with the anti-oxidant and anti-inflammatory drug NAC in a unique pro-drug., (© 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.)

A few ruthenium based metal carbonyl complexes, e.g. CORM-2 and CORM-3, have therapeutic activity attributed to their ability to deliver CO to biological targets. In this work, a series of related complexes with the formula [Ru(CO)3Cl2L] (L = DMSO (3), L-H3CSO(CH2)2CH(NH2)CO2H) (6a); D,L-H3CSO(CH2)2CH(NH2)CO2H (6b); 3-NC5H4(CH2)2SO3Na (7); 4-NC5H4(CH2)2SO3Na (8); PTA (9); DAPTA (10); H3CS(CH2)2CH(OH)CO2H (11); CNCMe2CO2Me (12); CNCMeEtCO2Me (13); CN(c-C3H4)CO2Et) (14)) were designed, synthesized and studied. The effects of L on their stability, CO release profile, cytotoxicity and anti-inflammatory properties are described. The stability in aqueous solution depends on the nature of L as shown using HPLC and LC-MS studies. The isocyanide derivatives are the least stable complexes, and the S-bound methionine oxide derivative is the more stable one. The complexes do not release CO gas to the headspace, but release CO2 instead. X-ray diffraction of crystals of the model protein Hen Egg White Lysozyme soaked with 6b (4UWN) and 8 (4UWN) shows the addition of Ru(II)(CO)(H2O)4 at the His15 binding site. Soakings with 7(4UWN) produced the metallacarboxylate [Ru(COOH)(CO)(H2O)3](+) bound to the His15 site. The aqueous chemistry of these complexes is governed by the water-gas shift reaction initiated with the nucleophilic attack of HO(-) on coordinated CO. DFT calculations show this addition to be essentially barrierless. The complexes have low cytotoxicity and low hemolytic indices. Following i.v. administration of CORM-3, the in vivo bio-distribution of CO differs from that obtained with CO inhalation or with heme oxygenase stimulation. A mechanism for CO transport and delivery from these complexes is proposed.

We report the design and synthesis of an aquacarbonyl Ru(II) dication cis-[Ru(CO)2(H2O)4](2+) reagent for histidine (His)-selective metallation of interleukin (IL)-8 at site 33. The artificial, non-toxic interleukin (IL)-8-Ru(II)(CO)2 metalloprotein retained IL-8-dependent neutrophil chemotactic activity and was shown to spontaneously release CO in live cells.

We demonstrate that Ru(II)(CO)2-protein complexes, formed by the reaction of the hydrolytic decomposition products of [fac-RuCl(κ(2)-H2NCH2CO2)(CO)3] (CORM-3) with histidine residues exposed on the surface of proteins, spontaneously release CO in aqueous solution, cells, and mice. CO release was detected by mass spectrometry (MS) and confocal microscopy using a CO-responsive turn-on fluorescent probe. These findings support our hypothesis that plasma proteins act as CO carriers after in vivo administration of CORM-3. CO released from a synthetic bovine serum albumin (BSA)-Ru(II)(CO)2 complex leads to downregulation of the cytokines interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α in cancer cells. Finally, administration of BSA-Ru(II)(CO)2 in mice bearing a colon carcinoma tumor results in enhanced CO accumulation at the tumor. Our data suggest the use of Ru(II)(CO)2-protein complexes as viable alternatives for the safe and spatially controlled delivery of therapeutic CO in vivo., (© 2014 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.)

A Zn-Al layered double hydroxide (LDH) intercalated by [Mo(η(3)-C3H5)Cl(CO)2(bpdc)](2-) anions (bpdc = 2,2'-bipyridine-5,5'-dicarboxylate) has been prepared by coprecipitation from aqueous solution and characterised by various techniques. The one-pot method gives rise to a highly organised intercalate with an interlayer spacing of 18.3 Å and up to six (00l) basal reflections in the powder X-ray diffraction pattern. Spectroscopic studies (FT-IR, FT-Raman, (13)C CP MAS NMR and UV-Vis) confirm the presence of structurally intact [Mo(η(3)-C3H5)Cl(CO)2(bpdc)](2-) anions. The interlayer spacing of 18.3 Å indicates that the material contains a monolayer of guest anions positioned in such a way that the bpdc ligands are arranged with their longest dimension roughly perpendicular to the hydroxide layers of the host. Thermal properties were studied by thermogravimetric analysis and differential scanning calorimetry. The intracrystalline reactivity of intercalated dicarbonyl complexes was probed by using the hybrid nanocomposite as a precatalyst in the liquid phase epoxidation of cis-cyclooctene with tert-butylhydroperoxide as oxidant. Under the reaction conditions used, oxidative decarbonylation of the guest molecules takes place (with release of CO and CO2 as confirmed by on-line gas chromatography experiments) to give intercalated molybdenum oxide/bipyridine species that selectively catalyse the epoxidation reaction. The intracrystalline oxidative decarbonylation reaction is topotactic in nature.

The complex fac-[Mo(CO)(3)(histidinate)]Na has been reported to be an effective CO-Releasing Molecule in vivo, eliciting therapeutic effects in several animal models of disease. The CO releasing profile of this complex in different settings both in vitro and in vivo reveals that the compound can readily liberate all of its three CO equivalents under biological conditions. The compound has low toxicity and cytotoxicity and is not hemolytic. CO release is accompanied by a decrease in arterial blood pressure following administration in vivo. We studied its behavior in solution and upon the interaction with proteins. Reactive oxygen species (ROS) generation upon exposure to air and polyoxomolybdate formation in soaks with lysozyme crystals were observed as processes ensuing from the decomposition of the complex and the release of CO.

Purpose: Carbon monoxide (CO) is an accepted cytoprotective molecule. The extent and mechanisms of protection in neuronal systems have not been well studied. We hypothesized that delivery of CO via a novel releasing molecule (CORM) would impart neuroprotection in vivo against ischemia-reperfusion injury (IRI)-induced apoptosis of retinal ganglion cells (RGC) and in vitro of neuronal SH-SY5Y-cells via activation of soluble guanylate-cyclase (sGC)., Methods: To mimic ischemic respiratory arrest, SH-SY5Y-cells were incubated with rotenone (100 nmol/L, 4 h) ± CORM ALF186 (10-100 µmol/L) or inactivated ALF186 lacking the potential of releasing CO. Apoptosis and reactive oxygen species (ROS) production were analyzed using flow-cytometry (Annexin V, mitochondrial membrane potential, CM-H2DCFDA) and Western blot (Caspase-3). The impact of ALF186± respiratory arrest on cell signaling was assessed by measuring expression of nitric oxide synthase (NOS) and soluble guanylate-cyclase (sGC) and by analyzing cellular cGMP levels. The effect of ALF186 (10 mg/kg iv) on retinal IRI in Sprague-Dawley rats was assessed by measuring densities of fluorogold-labeled RGC after IRI and by analysis of apoptosis-related genes in retinal tissue., Results: ALF186 but not inactivated ALF186 inhibited rotenone-induced apoptosis (Annexin V positive cells: 25 ± 2% rotenone vs. 14 ± 1% ALF186+rotenone, p<0.001; relative mitochondrial membrane potential: 17 ± 4% rotenone vs. 55 ± 3% ALF186+rotenone, p<0.05). ALF186 increased cellular cGMP levels (33±5 nmol/L vs. 23±3 nmol/L; p<0.05) and sGC expression. sGC-inhibition attenuated ALF186-mediated protection (relative mitochondrial membrane potential: 55±3% ALF186+rotenone vs. 20 ± 1% ODQ + ALF186+rotenone, p<0.05). ALF186 protected RGC in vivo (IRI 1255 ± 327 RGC/mm(2) vs. ALF186 + IRI 2036 ± 83; p<0.05) while sGC inhibition abolished the protective effects of ALF186 (ALF186 + IRI 2036 ± 83 RGC/mm(2) vs. NS-2028 + ALF186 + IRI 1263 ± 170, p<0.05)., Conclusions: The CORM ALF186 inhibits IRI-induced neuronal cell death via activation of sGC and may be a useful treatment option for acute ischemic insults to the retina and the brain.

Complexes of the general formula fac-[Ru(CO)(3)L(3)](2+), namely CORM-2 and CORM-3, have been successfully used as experimental CO releasing molecules (CO-RMs) but their mechanism of action and delivery of CO remain unclear. The well characterized complex [Ru(CO)(3)Cl(2)(1,3-thiazole)] (1) is now studied as a potential model CO-RM of the same family of complexes using LC-MS, FTIR, and UV-vis spectroscopy, together with X-ray crystallography. The chemistry of [Ru(CO)(3)Cl(2)(1,3-thiazole)] is very similar to that of CORM-3: it only releases residual amounts of CO to the headspace of a solution in PBS7.4 and produces marginal increase of COHb after long incubation in whole blood. 1 also reacts with lysozyme to form Ru adducts. The crystallographic model of the lysozyme-Ru adducts shows only mono-carbonyl Ru species. [Ru(H(2)O)(4)(CO)] is found covalently bound to a histidine (His15) and to two aspartates (Asp18 and Asp119) at the protein surface. The CO release silence of both 1 and CORM-3 and their rapid formation of protein-Ru(CO)(x)(H(2)O)(y) (x=1,2) adducts, support our hypothesis that fac-[Ru(CO)(3)L(3)] CO-RMs deliver CO in vivo through the decay of their adducts with plasma proteins., (Copyright © 2012 Elsevier Inc. All rights reserved.)

The use of Carbon Monoxide (CO) as a therapeutic agent has already been tested in human clinical trials. Pre-clinically, CO gas administration proved beneficial in animal models of various human diseases. However, the use of gaseous CO faces serious obstacles not the least being its well-known toxicity. To fully realise the promise of CO as a therapeutic agent, it is key to find novel avenues for CO delivery to diseased tissues in need of treatment, without concomitant formation of elevated, toxic blood levels of carboxyhemoglobin (COHb). CO-releasing molecules (CO-RMs) have the potential to constitute safe treatments if CO release in vivo can be controlled in a spatial and temporal manner. It has already been demonstrated in animals that CO-RMs can release CO and mimic the therapeutic effects of gaseous CO. While demonstrating the principle of treatment with CO-RMs, these first generation compounds are not suitable for human use. This tutorial review summarises the biological and chemical behaviour of CO, the current status of CO-RM development, and derives principles for the creation of the next generation of CO-RMs for clinical applications in humans., (This journal is © The Royal Society of Chemistry 2012)

The oxidative decarbonylation of the η(3)-allyl dicarbonyl complexes [Mo(η(3)-C(3)H(5))Cl(CO)(2)(L)] (L = 2,2'-bipyridine (bipy) (1), 4,4'-di-tert-butyl-2,2'-bipyridine (di-tBu-bipy) (2)) by reaction with aqueous tert-butylhydroperoxide (TBHP) or H(2)O(2) gave the following compounds in good to excellent yields: the oxo-bridged dimers [MoO(2)Cl(L)](2)O (L = bipy (3), di-tBu-bipy (6)) using TBHP(10 equiv.)/CH(3)CN/r.t.; the molybdenum oxide/bipyridine hybrid material {[MoO(3)(bipy)][MoO(3)(H(2)O)]}(n) (4) and the octanuclear complex [Mo(8)O(24)(di-tBu-bipy)(4)] (7) using TBHP(50 equiv.)/H(2)O/70 °C; the oxodiperoxo complexes MoO(O(2))(2)(L) (L = bipy (5), di-tBu-bipy (8)) using H(2)O(2)(10 equiv.)/CH(3)CN/r.t. The structure of 7·x(solvent) (where solvent = CH(2)Cl(2) and/or diethyl ether) was determined by single crystal X-ray diffraction. Despite possessing the same windmill-type complex as that described previously for 7·10CH(2)Cl(2), the crystal structure of 7·x(solvent) is unique due to differences in the crystal packing. Compounds 1-8 were examined as catalysts or catalyst precursors for the epoxidation of cyclooctene using aqueous TBHP or H(2)O(2) as oxidant at 55 or 70 °C. Reactions were performed without co-solvent or with the addition of water, ethanol or acetonitrile. Cyclooctene oxide was always the only reaction product. Solids recovered after 24 h reaction at 70 °C were identified by FT-IR spectroscopy as the hybrid 4 from (1,3-5)/TBHP, complex 5 from (1,3-5)/H(2)O(2), and complex 8 from (2,6-8)/H(2)O(2). With TBHP as oxidant, the highest epoxide yields (for 24 h reaction at 70 °C) were obtained using excess H(2)O as solvent (28-38% for 1,3-5; 87-98% for 2,6-8), while with H(2)O(2) as oxidant, the highest epoxide yields were obtained using CH(3)CN as solvent (54-81% for 3-8).

Severe forms of malaria infection, such as cerebral malaria (CM) and acute lung injury (ALI), are mainly caused by the apicomplexan parasite Plasmodium falciparum. Primary therapy with quinine or artemisinin derivatives is generally effective in controlling P. falciparum parasitemia, but mortality from CM and other forms of severe malaria remains unacceptably high. Herein, we report the design and synthesis of a novel carbon monoxide-releasing molecule (CO-RM; ALF492) that fully protects mice against experimental CM (ECM) and ALI. ALF492 enables controlled CO delivery in vivo without affecting oxygen transport by hemoglobin, the major limitation in CO inhalation therapy. The protective effect is CO dependent and induces the expression of heme oxygenase-1, which contributes to the observed protection. Importantly, when used in combination with the antimalarial drug artesunate, ALF492 is an effective adjunctive and adjuvant treatment for ECM, conferring protection after the onset of severe disease. This study paves the way for the potential use of CO-RMs, such as ALF492, as adjunctive/adjuvant treatment in severe forms of malaria infection.

Objective: Carbon monoxide (CO) is a weak soluble guanylyl cyclase stimulator, leading to transient increases in cGMP and vasodilation. The aim of the present work was to measure the effect of CO-releasing molecules (CORMs) on the cGMP/nitric oxide (NO) pathway and to evaluate how selected CORMs affect NO-induced vasorelaxation., Methods and Results: Incubation of smooth muscle cells with some but not all of the CORMs caused a minor increase in cGMP levels. Concentration-response curves were bell-shaped, with higher CORMs concentrations producing lower increases in cGMP levels. Although exposure of cells to CORM-2 enhanced cGMP formation, we observed that the compound inhibited NO-stimulated cGMP accumulation in cells and NO-stimulated soluble guanylyl cyclase activity that could be reversed by superoxide anion scavengers. Reactive oxygen species generation from CORMs was confirmed using luminol-induced chemiluminescence and electron spin resonance. Furthermore, we observed that NO is scavenged by CORM-2. When used alone CORM-2 relaxed vessels through a cGMP-mediated pathway but attenuated NO donor-stimulated vasorelaxation., Conclusion: We conclude that the CORMs examined have context-dependent effects on vessel tone, as they can directly dilate blood vessels, but also block NO-induced vasorelaxation.

The macrocycle 1,4,7-trithiacyclononane (ttcn) reacts with [(η(5)-Ind)Mo(CO)(2)(NCMe)(2)](+) (or [(η(5)-Ind)Mo(CO)(2)(κ(2)-dme)](+)) to give [(η(3)-Ind)Mo(CO)(2)(κ(3)-ttcn)](+) as the BF(4)(-) salt (1), but its reaction with [(η(5)-Ind)Mo(CO)(2)(C(3)H(6))(FBF(3))] affords the C-S bond cleavage product [(η(5)-Ind)Mo(CO)(κ(3)-1,4,7-trithiaheptanate)]BF(4) (6), which has been characterised by X-ray crystallography (Ind = C(9)H(7), indenyl). In contrast to ttcn, the macrocycles 1,3,5-trithiane (tt) and 1,4,7,10-tetrathiacyclododecane (ttcd) fail to induce changes in the coordination mode of indenyl: tt and ttcd react with [(η(5)-Ind)Mo(CO)(2)(NCMe)(2)](+) (or [(η(5)-Ind)Mo(CO)(2)(κ(2)-dme)](+)) to give [(η(5)-Ind)Mo(CO)(2)(κ(2)-tt)](+) (2), characterised by X-ray crystallography, and [(η(5)-Ind)Mo(CO)(2)(κ(2)-ttcd)](+) (3), respectively. The cyclopentadienyl (Cp = C(5)H(5)) analogues [(η(5)-CpMo(CO)(2)(κ(2)-tt)](+) (4) and [(η(5)-CpMo(CO)(2)(κ(2)-ttcn)](+) (5) have also been synthesised and 5 characterised by X-ray crystallography. DFT calculations showed that the η(5)-Ind/Cp coordination mode is always the most stable. However, a molecular dynamics study of the macrocycles conformations revealed that the major conformer of ttcn was a chair, which favoured κ(3) coordination. As indenyl complexes undergo slippage with a small barrier (<10 kcal mol(-1)), the kinetically preferred species [(η(3)-Ind)Mo(CO)(2)(κ(3)-ttcn)](+) (1) is the observed one. The conversion to 6 proceeds stepwise, with loss of ethylene followed by loss of CO, as calculated by DFT, with a barrier of 38.7 kcal mol(-1), consistent with the slow uncatalysed reaction.

CO-releasing molecules (CO-RMs) were previously shown by us to be more potent bactericides than CO gas. This suggests a mechanism of action for CO-RM, which either potentiates the activity of CO or uses another CO-RM-specific effect. We have also reported that CORM-2 induces the expression of genes related to oxidative stress. In the present study we intend to establish whether the generation of reactive oxygen species by CO-RMs may indeed result in the inhibition of bacterial cellular function. We now report that two CO-RMs (CORM-2 and ALF062) stimulate the production of ROS in Escherichia coli, an effect that is abolished by addition of antioxidants. Furthermore, deletion of genes encoding E. coli systems involved in reactive oxygen species scavenging, namely catalases and superoxide dismutases, potentiates the lethality of CORM-2 due to an increase of intracellular ROS content. CORM-2 also induces the expression of the E. coli DNA repair/SOS system recA, and its inactivation enhances toxicity of CORM-2. Moreover, fluorescence microscopy images reveal that CORM-2 causes DNA lesions to bacterial cells. We also demonstrate that cells treated with CORM-2 contain higher levels of free iron arising from destruction of iron-sulfur proteins. Importantly, we show that CO-RMs generate hydroxyl radicals in a cell-free solution, a process that is abolished by scavenging CO. Altogether, we provide a novel insight into the molecular basis of CO-RMs action by showing that their bactericidal properties are linked to cell damage inflicted by the oxidative stress that they are able to generate.

CORM-3, [fac-Ru(CO)(3)Cl(κ(2)-H(2)NCH(2)CO(2))], is a well-known carbon monoxide releasing molecule (CORM) capable of delivering CO in vivo. Herein we show for the first time that the interactions of CORM-3 with proteins result in the loss of a chloride ion, glycinate, and one CO ligand. The rapid formation of stable adducts between the protein and the remaining cis-Ru(II)(CO)(2) fragments was confirmed by Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES), Liquid-Chromatography Mass Spectrometry (LC-MS), Infrared Spectroscopy (IR), and X-ray crystallography. Three Ru coordination sites are observed in the structure of hen egg white lysozyme crystals soaked with CORM-3. The site with highest Ru occupancy (80%) shows a fac-[(His15)Ru(CO)(2)(H(2)O)(3)] structure.

The title compound, [Mo(2)(C(5)H(10)NS(2))(2)O(4)]·C(4)H(8)O, can be readily prepared in tetra-hydro-furan (THF) by an oxidation reaction between the Mo(IV) precursor [MoO(S(2)CNEt(2))(2)] with [ReMeO(3)]. The compound is an axially symmetric Mo(V) dimer (2 symmetry), in which the metal atoms exhibit a distorted square-pyramidal coordination environment. A THF mol-ecule was found to be equally disordered over two symmetry-related sites (around a twofold rotation axis), trans-coordinated to the apical oxido group and weakly inter-acting with the Mo(V) atoms [Mo-O = 2.6213 (19) Å]. In the crystal, some weak C-H⋯O inter-actions occur between the terminal oxido and neighbouring -CH(3) groups of an adjacent [Mo(μ-O)O(S(2)CNEt(2))](2) unit.

The biological role of carbon monoxide (CO) has completely changed in the last decade. Beyond its widely feared toxicity, CO has revealed a very important biological activity as a signaling molecule with marked protective actions namely against inflammation, apoptosis and endothelial oxidative damage. Its direct use as a therapeutic gas showed significant and consistent positive results but also intrinsic severe limitations. The possibility of replacing the gas by pro-drugs acting as CO-Releasing Molecules (CO-RMs) has clearly been demonstrated with several experimental compounds. Transition metal carbonyls complexes have proven to be the most versatile experimental CO-RMs so far. Presently, the challenge is to equip them with drug-like properties to turn them into useful pharmaceuticals. This requires studying their interactions with biological molecules namely those that control their pharmacokinetic and ADME profiles like the plasma proteins. In this account we analyze these questions and review the existing interactions between Metal Carbonyls and proteins. The recently explored case of CORM-3 is revisited to exemplify the methodologies involved and the importance of the results for the understanding of the mode of action of such pro-drugs.

The temperature-composition phase diagrams of 40 binary mixtures composed of a haloalkane dissolved in either 1-ethyl-3-methylimidazolium ethylsulfate or 1-ethyl-3-methylimidazolium ethylsulfonate were measured from ambient temperature to the boiling point temperature of the solute. The coexistence curves corresponding to liquid-liquid equilibria (LLE) boundaries were visually determined and the experimental results have been correlated using either the nonrandom two-liquid (NRTL) model or a set of empirical equations capable of describing the corresponding upper critical solution temperatures (UCSTs) loci. The different types of LLE behavior were discussed in terms of the type of ionic liquid solvent, the alkyl-chain length of the solute, and the type and pattern of halogen substitution present in the haloalkane. Auxiliary simulation data (obtained by ab initio or by molecular dynamics methods) were used to corroborate some of the experimental findings. Also, they correlate in a semiquantitative way the observed LLE behavior with the dipole moments of the different solutes.

The reaction of FeI(2) with two equivalents of AgReO(4) in acetonitrile leads to yellow, crystalline Fe(ReO(4))(2)(CH(3)CN)(3) (1), and the treatment of 1 with four equivalents of CpFe(CO)(2)CN gives orange, crystalline Fe(ReO(4))(2)[CpFe(CO)(2)(CN)](4) (2). Compound 2 can also be prepared in one step by the reaction of FeI(2), AgReO(4) and CpFe(CO)(2)CN in dichloromethane. The structure of 1 consists of infinite chains in which alternating {Fe(CH(3)CN)(4)} and {Fe(ReO(4))(2)(CH(3)CN)(2)} units are linked by perrhenate anions to form a (-ReO(2)-O-Fe(ReO(4))(2)(CH(3)CN)(2)-O-ReO(2)-O-Fe(CH(3)CN)(4)-O-)(n) molecular wire. The structure of 2 shows a monomeric iron complex with a slightly distorted octahedral coordination environment consisting of four organometallic complexes coordinated in the equatorial plane via the cyanide groups and two monodentate perrhenates in the corresponding apical positions. Both compounds were further characterised in the solid state by IR spectroscopy, thermogravimetric analysis and magnetic susceptibility measurements. The magnetic data indicate that 1 behaves as a ferrimagnetic chain with 3D ordering below 8 K due to inter-chain interactions. Compound 2 has antiferromagnetic interactions within the Fe(ReO(4))(2)[CpFe(CO)(2)(CN)](4) clusters.

The catalytic mechanism of nitrate reduction by periplasmic nitrate reductases has been investigated using theoretical and computational means. We have found that the nitrate molecule binds to the active site with the Mo ion in the +6 oxidation state. Electron transfer to the active site occurs only in the proton-electron transfer stage, where the Mo(V) species plays an important role in catalysis. The presence of the sulfur atom in the molybdenum coordination sphere creates a pseudo-dithiolene ligand that protects it from any direct attack from the solvent. Upon the nitrate binding there is a conformational rearrangement of this ring that allows the direct contact of the nitrate with Mo(VI) ion. This rearrangement is stabilized by the conserved methionines Met141 and Met308. The reduction of nitrate into nitrite occurs in the second step of the mechanism where the two dimethyl-dithiolene ligands have a key role in spreading the excess of negative charge near the Mo atom to make it available for the chemical reaction. The reaction involves the oxidation of the sulfur atoms and not of the molybdenum as previously suggested. The mechanism involves a molybdenum and sulfur-based redox chemistry instead of the currently accepted redox chemistry based only on the Mo ion. The second part of the mechanism involves two protonation steps that are promoted by the presence of Mo(V) species. Mo(VI) intermediates might also be present in this stage depending on the availability of protons and electrons. Once the water molecule is generated only the Mo(VI) species allow water molecule dissociation, and, the concomitant enzymatic turnover., (Copyright 2009 Wiley Periodicals, Inc.)

The reduction of aromatic nitro compounds to the corresponding amines with silanes catalyzed by high valent oxo-rhenium complexes is reported. The catalytic systems PhMe(2)SiH/ReIO(2)(PPh(3))(2) (5 mol %) and PhMe(2)SiH/ReOCl(3)(PPh(3))(2) (5 mol %) reduced efficiently a series of aromatic nitro compounds in the presence of a wide range of functional groups such as ester, halo, amide, sulfone, lactone, and benzyl. This methodology also allowed the regioselective reduction of dinitrobenzenes to the corresponding nitroanilines and the reduction of an aromatic nitro group in presence of an aliphatic nitro group.

The isolation and structural characterization by X-ray diffraction of (PPh(3))(2)(O)(I)Re(H)OBcat and (PPh(3))(2)(O)(I)Re(H)OBpin from the reaction of ReIO(2)(PPh(3))(2) with the boranes catecholborane (HBcat) and pinacolborane (HBpin) unequivocally shows the first example of activation of B-H bond by a high valent oxo-rhenium complex.

Nitrate reductase from Desulfovibrio desulfuricans ATCC 27774 (DdNapA) is a monomeric protein of 80 kDa harboring a bis(molybdopterin guanine dinucleotide) active site and a [4Fe-4S] cluster. Previous electron paramagnetic resonance (EPR) studies in both catalytic and inhibiting conditions showed that the molybdenum center has high coordination flexibility when reacted with reducing agents, substrates or inhibitors. As-prepared DdNapA samples, as well as those reacted with substrates and inhibitors, were crystallized and the corresponding structures were solved at resolutions ranging from 1.99 to 2.45 A. The good quality of the diffraction data allowed us to perform a detailed structural study of the active site and, on that basis, the sixth molybdenum ligand, originally proposed to be an OH/OH(2) ligand, was assigned as a sulfur atom after refinement and analysis of the B factors of all the structures. This unexpected result was confirmed by a single-wavelength anomalous diffraction experiment below the iron edge (lambda = 1.77 A) of the as-purified enzyme. Furthermore, for six of the seven datasets, the S-S distance between the sulfur ligand and the Sgamma atom of the molybdenum ligand Cys(A140) was substantially shorter than the van der Waals contact distance and varies between 2.2 and 2.85 A, indicating a partial disulfide bond. Preliminary EPR studies under catalytic conditions showed an EPR signal designated as a turnover signal (g values 1.999, 1.990, 1.982) showing hyperfine structure originating from a nucleus of unknown nature. Spectropotentiometric studies show that reduced methyl viologen, the electron donor used in the catalytic reaction, does not interact directly with the redox cofactors. The turnover signal can be obtained only in the presence of the reaction substrates. With use of the optimized conditions determined by spectropotentiometric titration, the turnover signal was developed with (15)N-labeled nitrate and in D(2)O-exchanged DdNapA samples. These studies indicate that this signal is not associated with a Mo(V)-nitrate adduct and that the hyperfine structure originates from two equivalent solvent-exchangeable protons. The new coordination sphere of molybdenum proposed on the basis of our studies led us to revise the currently accepted reaction mechanism for periplasmic nitrate reductases. Proposals for a new mechanism are discussed taking into account a molybdenum and ligand-based redox chemistry, rather than the currently accepted redox chemistry based solely on the molybdenum atom.

The high-valent oxo-molybdenum(VI) and -rhenium(VII) and -(V) derivatives MoO2Cl2, ReCH3O3 (MTO) and ReIO2(PPh3)2 catalyze the selective hydrogenation of alkynes to alkenes at 80 degrees C under 40 atm of pressure. The reduction of sulfoxides to sulfides has also been performed by oxo-rhenium and -molybdenum complexes using hydrogen as a reducing agent. Activation of hydrogen by MoO2Cl2 and MoO2(S2CNEt2)2 was shown by means of DFT calculations to proceed by H-H addition to the Mo=O bond, followed by hydride migration to yield a water complex.

Carbon monoxide (CO) is endogenously produced in the human body, mainly from the oxidation of heme catalyzed by heme oxygenase (HO) enzymes. The induction of HO and the consequent increase in CO production play important physiological roles in vasorelaxation and neurotransmission and in the immune system. The exogenous administration of CO gas and CO-releasing molecules (CO-RMs) has been shown to induce vascular effects and to alleviate hypoxia-reoxygenation injury of mammalian cells. In particular, due to its anti-inflammatory, antiapoptotic, and antiproliferative properties, CO inhibits ischemic-reperfusion injury and provides potent cytoprotective effects during organ and cell transplantation. In spite of these findings regarding the physiology and biology of mammals, nothing is known about the action of CO on bacteria. In the present work, we examined the effect of CO on bacterial cell proliferation. Cell growth experiments showed that CO caused the rapid death of the two pathogenic bacteria tested, Escherichia coli and Staphylococcus aureus, particularly when delivered through organometallic CO-RMs. Of importance is the observation that the effectiveness of the CO-RMs was greater in near-anaerobic environments, as many pathogens are anaerobic organisms and pathogen colonization occurs in environments with low oxygen concentrations. Our results constitute the first evidence that CO can be utilized as an antimicrobial agent. We anticipate our results to be the starting point for the development of novel types of therapeutic drugs designed to combat antibiotic-resistant pathogens, which are widespread and presently a major public health concern.

Sertraline hydrochloride (designated as sertraline from now on) is an antidepressive drug with unpleasant effects in the gastric tract. Therefore, improved means of delivery allowing for a more controlled and efficient release were looked for. Two different porous materials, montmorillonite-K10 and MCM-41, were chosen as hosts. The drug was intercalated in the interlayer spacing of the clay by cation exchange and was loaded inside the MCM-41 channels by pore volume impregnation means. Spectroscopic evidence (UV/vis, FTIR, powder X-ray diffraction (XRD) and (13)C CP/MAS and (29)Si CP/MAS and MAS solid-state NMR), as well as elemental analysis, complemented by DFT calculations, demonstrated the presence of sertraline in the composite materials. The release processes were monitored under in vitro conditions using a simulated body fluid. The release profile from the clay is fast, indicating that a concentration peak is reached in a short period of time, while the release profile from MCM is slower but lasts longer. These differences are discussed on the basis of different therapeutic indications for both materials.

[MoCl(2)O(2)] catalyzes the hydrosilylation reaction of aldehydes and ketones, as well as the reduction of other related groups, in apparent contrast to its known behavior as an oxidation catalyst. In this work, the mechanism of this reaction is studied by means of density functional theory calculations using the B3LYP functional complemented by experimental data. We found that the most favorable pathway to the first step, the Si--H activation, is a [2+2] addition to the Mo=O bond, in agreement with previous and related work. The stable intermediate that results is a distorted-square-pyramidal hydride complex. In the following step, the aldehyde approaches this species and coordinates weakly through the oxygen atom. Two alternative pathways can be envisaged: the classical reduction, in which a hydrogen atom migrates to the carbon atom to form an alkoxide, which then proceeds to generate the final silyl ether, or a concerted mechanism involving migration of a hydrogen atom to a carbon atom and of a silyl group to an oxygen atom to generate the silyl ether weakly bound to the molybdenum atom. In this Mo(VI) system, the gas-phase free energies of activation for both approaches are very similar, but if solvent effects are taken into account and HSiMe(3) is used as a source of silicon, the classical mechanism is favored. Several unexpected results led us to search for still another route, namely a radical path. The energy involved in this and the classical pathway are similar, which suggests that hydrosilylation of aldehydes and ketones catalyzed by [MoCl(2)O(2)] in acetonitrile may follow a radical pathway, in agreement with experimental results.

The dioxomolybdenum(VI) complexes [MoO2Cl2] (1), [MoO2(acac)2] (2), [MoO2(S2CNEt2)2] (3), [CpMoO2Cl] (4), [MoO2(mes)2] (5) and the polymeric organotin-oxomolybdates [(R3Sn)2MoO4] [R = n-Bu (6), t-Bu (7), Me (8)] were examined as catalysts for the hydrosilylation of aldehydes and ketones with dimethylphenylsilane. Of these, [MoO2Cl2] (1) was the most efficient catalyst, affording quantitative yields of the corresponding silylated ethers at room temperature in acetonitrile. Complexes 2, 4-8 also catalyzed the same reaction but required heating at 80 degrees C and longer reaction times compared with 1. Compound 3 is inactive. The wide scope of molybdenum oxide-mediated hydrosilylation was established with a variety of aldehydes and ketones. Counter intuitively, the activity of is 1 highest in NCMe. In the absence of a carbonyl substrate, [MoO2Cl2(NCBu(t))] (10) reacts with HSiMe2Ph affording [MoO(OSiMe2Ph)Cl2]2 (11) which has been fully characterized by NMR and IR spectroscopy, elemental analyses and mass spectrometry. Addition of radical scavengers strongly slows down the [MoO2Cl2]-based hydrosilylation suggesting the intermediacy of oxygen-centered radicals.

DFT calculations suggest that the catalytic epoxidation of olefins by Mo(vi) complexes, modeled by MoO2Br2(MeN=C(H)-C(H)=NMe), in the presence of MeOOH, the model for tert-butyl hydroperoxide, starts with a hydrogen transfer from the peroxide to one of the terminal Mo=O oxygen atoms and the remaining MeOO anion binds as a seventh ligand, forming a five-membered Mo-O(alpha)-O(beta)(Me)...H-O-Mo ring held together by a hydrogen bond. In the second step, a concerted approach of ethylene to the Mo-O(alpha) bond gives rise to an intermediate containing a seven-membered Mo-C-C-O(alpha)-O(beta)(Me)...H-O-Mo ring. In the final step, decomposition of the intermediate leads to the starting complex, alcohol and the epoxide. The activation energy for the addition of the olefin (second step) is the highest one, in agreement with available kinetic studies showing that the catalyst formation is not always a rate-limiting step. DFT calculations also show that the alcohol by-product (MeOH) can react with the starting complex, competing with ROOH and hence leading to the progressive catalyst poisoning, which has been observed experimentally.

Several oxorhenium compounds in the formal oxidation states V and VII are examined as catalysts for the aldehyde-olefination starting from diazo compounds, phosphines, and aldehydes. Of these, [ReMeO2(eta2-alkyne)] complexes provide the simplest catalysts to study, although [ReOCl3(PPh3)2] still remains the most efficient rhenium catalyst for aldehyde-olefination described to date. Prior to the reaction with the Re catalysts the phosphine and the diazo compound react to form a phosphazine. No catalytic reaction occurs in cases where no phosphazine formation is observed. The first step of the catalytic cycle involves the formation of a carbene intermediate by the reaction of phosphazine and catalyst under extrusion of phosphine oxide and dinitrogen. In a second step the carbene reacts with aldehyde under olefin formation and catalyst regeneration. Excess of alkyne as well as the presence of ketones slows down the catalytic reaction. The olefination of 4-nitrobenzaldehyde with diazomalonate is possible with these Re catalysts. In contrast, this reaction does not take place either in the classical Wittig fashion from Ph3P=C(CO2Et)2 and aldehyde or by use of all other catalysts for aldehyde olefination reactions reported to date. Catalytic ylide formation from diazo compounds seems therefore not to be the only pathway through which catalytic aldehyde-olefination reactions can proceed.

The organotin-oxomolybdates [(R(3)Sn)(2)MoO(4)].n H(2)O (R=methyl, n-butyl, cyclohexyl, phenyl, benzyl) have been prepared and tested as catalysts for the oxidation of benzothiophene with aqueous hydrogen peroxide, at 35 degrees C and atmospheric pressure. In all cases, the 1,1-dioxide was the only observed product. The kinetic profiles depend on the nature of the tin-bound R group and also on the addition of a co-solvent. For the tribenzyltin derivative, the apparent activation energies for sulfoxidation as a function of the co-solvent are in the order 1,2-dichloroethane (5 kcal mol(-1))

Crystalline 1:1 inclusion complexes with beta-cyclodextrin (beta-CD) and the sodium salt of nimesulide (4-nitro-2-phenoxymethanesulfonanilide), and the sodium salt of the derivative 2-phenoxymethanesulfonanilide, have been prepared by co-precipitation from aqueous solution. The presence of true inclusion complexes was supported by elemental analysis, thermogravimetry and powder X-ray diffraction. FTIR and 13C CP MAS NMR spectroscopy confirmed that no chemical modification of the guests occurred upon formation of inclusion complexes. The reaction of the precursors 2-phenoxynitrobenzene and 2-phenoxyaniline with beta-CD was also studied and crystalline inclusion complexes with a 2:1 (host-to-guest) stoichiometry were isolated. The interaction of the different guest species with beta-CD host molecules was studied theoretically by carrying out ab initio calculations. Favourable inclusion geometries were obtained for the four guests mentioned above. On the other hand, it was found that the inclusion of the neutral guests nimesulide and 2-phenoxymethanesulfonanilide was considerably less favourable. This is in agreement with the experimentally observed difficulty in isolating true inclusion complexes containing these guests and beta-CD. The calculated lower stability is attributed to the different steric hindrance arising from the different conformational preferences of neutral and anionic forms.

Complexes CH3ReO2L (L = 2-butyne, 3-hexyne, diphenylacetylene) are catalysts for the olefination of aldehydes, using 4-nitrobenzaldehyde (4-nba) as the standard aldehyde and ethyldiazoacetate (eda) as the diazo compound. Spectroscopic studies including in situ 31P, 17O, 13C, and 1H NMR spectroscopy are used to elucidate the mechanism and the nature of the active species. One of the key steps of the mechanism is the rapid formation of phosphazine at the beginning of the cycle and its subsequent reaction with the metal dioxide complex to form the catalytically active carbene species.

Complexes of the composition W(O)(2)(Cl)(2)L(2) and W(O)(2)(R)(2)L(2) (R = Me, Et; L(2) = bidentate Lewis base ligand) have been prepared and are fully characterized (including an exemplary X-ray crystal structure of W(O)(2)(Cl)(2)(4,4'-di-tert-butyl-2,2'-bipyridine)). This latter compound crystallizes in the orthorhombic space group P2(1)2(1)2(1) with a = 8.3198(1) A, b = 13.3224(2) A, c = 18.0415(2) A, and Z = 4. The title complexes are applied as catalysts in olefin epoxidation catalysis with tert-butyl hydroperoxide (TBHP) as the oxidizing agent. The W(VI) complexes display only moderate turnover frequencies but can be reused several times without loss of catalytic activity. The highest activity can be achieved at reaction temperatures of ca. 90 degrees C. Chloro derivatives are somewhat more active than alkyl complexes, and sterically less crowded complexes show also higher activities than their congeners with bulky ligands L(2). Kinetic examinations show that the catalyst formation is the rate determining step and it is observed that tert-butyl alcohol, the byproduct of the epoxidation reaction, acts as a competitor for TBHP, thus lowering the reaction velocity during the course of the reaction but not irreversibly destroying the catalyst.

Complexes of the general formula [MoO(2)X(2)L(2)] (X=Cl, Br, Me; L(2)=bipy, bpym) have been prepared and fully characterized, including X-ray crystallographic investigations of all six compounds. Additionally, the highly soluble complex [MoO(2)Cl(2)(4,4'-bis(hexyl)-2,2'-bipyridine)] has been synthesized. The reaction of the complexes with tert-butyl hydroperoxide (TBHP) is an equilibrium reaction, and leads to MoV(I) eta(1)-alkylperoxo complexes that selectively catalyze the epoxidation of olefins. Neither the Mo-X bonds nor the Mo-N bonds are cleaved during this reaction. These experimental results are supported by theoretical calculations, which show that the attack of TBHP at the Mo center through the X-O-N face is energetically favored and the TBHP hydrogen atom is transferred to a terminal oxygen of the Mo=O moiety. After the attack of the olefin on the Mo-bound peroxo oxygen atom, epoxide and tert-butyl alcohol are formed. The latter compound acts as a competitive inhibitor for the TBHP attack, and leads to a significant reduction in the catalytic activity with increasing reaction time.